Besse B - Search Results

1

[What is the best sequence of treatment for patients with EGFR mutations?].

Besse B, Zalcman G. Besse B, et al. Rev Pneumol Clin. 2011 Jun;67 Suppl 1:S24-9. doi: 10.1016/S0761-8417(11)70007-4. Rev Pneumol Clin. 2011. PMID: 21777763 French.

2

[Small cell lung cancer (CPC). Management of patients presenting with limited stage small cell carcinoma of the lung].

Le Péchoux C, Besse B, Ferreira I, Bretel JJ, Bruna A, Mazeron R, Amarouch A, Roberti E. Le Péchoux C, et al. Among authors: besse b. Rev Mal Respir. 2006 Nov;23(5 Pt 3):16S188-16S197. Rev Mal Respir. 2006. PMID: 17268357 Review. French.

3

[The role of radiotherapy in the management of patients with small cell lung cancer].

Daveau C, Le Péchoux C, Besse B, Ferreira I, Amarouch A, Vicenzi L, Elloumi F, Roberti E, Bretel JJ. Daveau C, et al. Among authors: besse b. Rev Mal Respir. 2007 Oct;24(8 Pt 2):6S171-9. Rev Mal Respir. 2007. PMID: 18235411 Review. French.

4

[Management of targeted molecular therapies toxicities in thoracic cancerology].

Rajpar S, Osio A, Besse B. Rajpar S, et al. Among authors: besse b. Rev Pneumol Clin. 2008 Apr;64(2):104-10. doi: 10.1016/j.pneumo.2008.04.006. Epub 2008 Jun 6. Rev Pneumol Clin. 2008. PMID: 18589292 Review. French.

5

[Prognostic and predictive factors in lung cancer].

Marijon H, Bouyon A, Vignot S, Besse B. Marijon H, et al. Among authors: besse b. Bull Cancer. 2009 Apr;96(4):391-404. doi: 10.1684/bdc.2009.0779. Bull Cancer. 2009. PMID: 19357014 Review. French.

6

[Impact of KRAS in standard treatment of non-small cell lung cancer (NSCLC) patients in 2009: prognostic and predictive value].

Planchard D, Loriot Y, Besse B. Planchard D, et al. Among authors: besse b. Bull Cancer. 2009 Dec;96 Suppl:S57-68. doi: 10.1684/bdc.2009.0997. Bull Cancer. 2009. PMID: 20034871 French.

7

[KRAS status versus EGFR status in lung cancer therapy].

Lacroix L, Besse B, Bidart JM, Bosq J. Lacroix L, et al. Among authors: besse b. Bull Cancer. 2009 Dec;96 Suppl:S75-83. doi: 10.1684/bdc.2009.0999. Bull Cancer. 2009. PMID: 20034873 Review. French.

8

[Second-line therapy in patients with malignant pleural mesothelioma. A French retrospective study (2005-2006)].

Margery J, Rivière F, Planchard D, Le Floch H, Ferrand FR, Mairovitz A, Besse B, Vaylet F, Ruffié P. Margery J, et al. Among authors: besse b. Rev Pneumol Clin. 2010 Sep;66(4):255-9. doi: 10.1016/j.pneumo.2010.07.013. Epub 2010 Sep 15. Rev Pneumol Clin. 2010. PMID: 20933167 French.

9

Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC).

Gauler TC, Besse B, Mauguen A, Meric JB, Gounant V, Fischer B, Overbeck TR, Krissel H, Laurent D, Tiainen M, Commo F, Soria JC, Eberhardt WEE. Gauler TC, et al. Among authors: besse b. Ann Oncol. 2012 Mar;23(3):678-687. doi: 10.1093/annonc/mdr255. Epub 2011 May 26. Ann Oncol. 2012. PMID: 21617019 Free article. Clinical Trial.

10

Phase Ib safety and pharmacokinetic study of volociximab, an anti-α5β1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer.

Besse B, Tsao LC, Chao DT, Fang Y, Soria JC, Almokadem S, Belani CP. Besse B, et al. Ann Oncol. 2013 Jan;24(1):90-6. doi: 10.1093/annonc/mds281. Epub 2012 Aug 16. Ann Oncol. 2013. PMID: 22904239 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

615 results

Search Page

Filters